News Releases

August 2, 2023

Lung Diagnostic Assessment Program Outreach Clinic in Napanee, ON Expedites Assessment and Diagnosis for Patients with Lung Cancer

June 21, 2023

Melanoma is on the rise in Canada but there are ways to take action this summer

June 13, 2023

Merck Canada’s Executive Director, Legal and Compliance & Chief Privacy Officer, Chantal Desbiens, honoured at the Canadian General Counsel Awards with Litigation Management award

October 12, 2022

Health Canada Approves KEYTRUDA^® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions 

September 13, 2022

Health Canada Approves KEYTRUDA^® (pembrolizumab) as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection

April 18, 2022

Health Canada Approves KEYTRUDA^® (pembrolizumab) for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgerys 

April 11, 2022

Health Canada Approves GARDASIL^®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers 

December 6, 2021

Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19 

December 3, 2021

Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada 

November 26, 2021

Kingston Health Sciences Centre Expands Lung Diagnostic Assessment Program to Napanee, ON

November 23, 2021

Health Canada Approves KEYTRUDA^® (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

November 8, 2021

Merck Canada and Guy Lafleur Team Up Against Lung Cancer  

October 1, 2021

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

September 13, 2021

Marwan Akar Appointed as President & Managing Director of Merck Canada

September 1, 2021

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

August 13, 2021

Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19

May10, 2021

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

October 12, 2022

Health Canada Approves KEYTRUDA^® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions 

November 23, 2021

Health Canada Approves KEYTRUDA^® (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

November 8, 2021

Merck Canada and Guy Lafleur Team Up Against Lung Cancer  

September 1, 2021

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

August 13, 2021

Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19

November 23, 2021

Health Canada Approves KEYTRUDA^® (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)